Comparison between Accelerated Partial Breast Irradiation with multicatheter interstitial brachytherapy and Whole Breast Irradiation, in clinical practice

• Published in: Clinical & translational oncology Vol. 24; no. 1; pp. 24 - 33
• Main Authors: Garduño-Sánchez, S., Villanego-Beltrán, I., de las Peñas-Cabrera, M. Dolores, Jaén-Olasolo, J.
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01-01-2022
• Subjects: Aged; Brachytherapy - instrumentation; Brachytherapy - methods; Breast Neoplasms - mortality; Breast Neoplasms - radiotherapy; Catheters; Disease-Free Survival; Female; Humans; Medicine; Medicine & Public Health; Middle Aged; Oncology; Quality of Life; Radiotherapy - adverse effects; Radiotherapy - methods; Research Article; Retrospective Studies; Survival Rate; Treatment Outcome; Accelerated partial breast irradiation; Breast; Brachytherapy; Cancer
• ISSN: 1699-048X; 1699-3055
• DOI: 10.1007/s12094-021-02664-z

Purpose
The aim of this study was to compare accelerated partial breast irradiation (APBI) with multicatheter interstitial brachytherapy (BT) and whole breast irradiation (WBI), in terms of toxicity, aesthetic result, quality of life and survival, in clinical practice.
Materials and methods
A comparative study of two prospectively recorded cohorts of 76 breast cancer patients who complied with the recommendations of GEC-ESTRO for APBI was conducted. The main objective was toxicity, quality of life measured through validated questionnaires and the aesthetic results. Secondary objectives were overall survival and disease-free survival.
Results
Seventy-six stage I/II breast cancer patients, with a mean age of 66 years entered the study. APBI group showed less acute G1-2 dermatitis (51.4 vs 94.9%,
p
 < 0.001) and late hyperpigmentation (0 vs 17.9%,
p
 = 0.04). There were no differences in aesthetic results, both assessed by the patient herself and by the doctor. Statistically significant differences in measures of quality of life were observed in favour of the APBI, both in EORTC QLQ-BR23 and body image scale questionnaires. With a median follow-up of 72 months (6 years), the estimated overall survival at 5 and 10 years was 96.8 and 77.7%, respectively, and disease-free survival at 5 and 10 years was 91.1 and 69.4%, respectively, without statistically significant differences between groups.
Discussion
APBI is an attractive alternative in candidate patients with initial breast cancer, with benefits in acute toxicity and quality of life and fewer visits to the hospital, without compromising tumor control or survival.